Our Portfolio

University of California, Santa Barbara

Kenneth Kosik, MD | CA

Project Overview

  • Academic/Nonprofit Organization Type
  • $300,000 Funding Amount
  • 4/1/22 — 4/1/24 Project Duration
  • Drug Discovery Program
  • Tau Target
  • Hit Identification Therapeutic Stage
  • Active Status

University of California, Santa Barbara

Kenneth Kosik, MD | CA

Discovery of selective LRP1 inhibitors to prevent tau uptake and spread

Abnormal tau spread is a predominant pathological hallmark of Alzheimer’s disease and subtypes of frontotemporal dementia (FTD). It is hypothesized to contribute to disease progression and cell death. Dr. Kosik is developing a small molecule that can stop the abnormal uptake and spread of tau through the brain. This ADDF funding will support Dr. Kosik to further develop his drug. This is a novel approach for targeting tau pathology for FTD. 

GET IN TOUCH